According to Zhitong Finance APP, JPMorgan released a report stating that Alibaba Health (00241) recently announced the acquisition of the Tmall drug sales platform from its parent company Alibaba (09988). The target business generated a total transaction amount of approximately RMB 9.575 billion in the year ended the end of March last year, with a total transaction consideration of RMB 8.075 billion, which is equivalent to approximately 0.76 times the valuation/platform total transaction amount. The bank added that the transaction sentiment was positive, stating that the timing of injecting the drug business was excellent, which would help Alibaba Health expand its online prescription drug sales platform in mainland China and further strengthen Alibaba Health's position as Alibaba's flagship health platform. It believes...
- Like
- Comment
- Favorite
JPMorgan: Maintains "Overweight" rating on Alibaba Health (00241) with a target price of HK$10.7
智通财经2020-02-10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet